2. UroToday Home
  3. Recent Abstracts
  4. Urologic Oncology
  5. Bladder Cancer

New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with Second-Line Immune Checkpoint Inhibitors - Beyond the Abstract

Bellmunt Risk Score, based on Eastern Cooperative Oncology Group (ECOG) performance status (PS), hemoglobin levels and presence of liver metastases, is the most established prognostic algorithm for patients with advanced urothelial cancer (aUC) progressing after platinum-based chemotherapy. Existing algorithms may not be sufficient following the introduction of immunotherapy. Our aim was to develop an improved prognostic model in patients receiving second-line atezolizumab for aUC.

New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with Second-Line Immune Checkpoint Inhibitors - Beyond the Abstract

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • subtitles off, selected


    PDL1.png

    atezo.png

    bellmunt.png

    Aristotelis Bamias, Second Propaedeutic Department of Internal Medicine, National and Kapodistrian University of Athens, Chaidari, Greece

    Read the Abstract